{
    "root": "b1a3f864-56e1-44da-b2d0-7158d0945513",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Arranon",
    "value": "20250331",
    "ingredients": [
        {
            "name": "NELARABINE",
            "code": "60158CV180",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_63612"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26710"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        }
    ],
    "indications": {
        "text": "arranon indicated treatment t-cell acute lymphoblastic leukemia ( t-all ) t-cell lymphoblastic lymphoma ( t-lbl ) adult pediatric patients age 1 year older whose disease responded relapsed following treatment least 2 chemotherapy regimens .",
        "doid_entities": [
            {
                "text": "t-cell acute lymphoblastic leukemia (DOID:5603)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5603"
            },
            {
                "text": "lymphoblastic leukemia (DOID:1037)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1037"
            },
            {
                "text": "leukemia (DOID:1240)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1240"
            },
            {
                "text": "lymphoblastic lymphoma (DOID:0080147)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0080147"
            },
            {
                "text": "lymphoma (DOID:0060058)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060058"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "acute lymphoblastic leukemia",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_513"
            }
        ]
    },
    "contraindications": {
        "text": "\u2022 adult dose : 1,500 mg/m 2 administered intravenous infusion 2 hours days 1 , 3 , 5 repeated every 21 days . ( 2.1 ) \u2022 pediatric dose : 650 mg/m 2 administered intravenous infusion 1 hour daily 5 consecutive days repeated every 21 days . ( 2.1 ) \u2022 discontinue treatment neurologic greater equal grade 2 . ( 2.2 ) \u2022 may delayed hematologic . ( 2.2 ) \u2022 take measures prevent hyperuricemia . ( 2.4 )",
        "doid_entities": [
            {
                "text": "hyperuricemia (DOID:1920)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1920"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "arranon ( nelarabine ) injection supplied clear , colorless , sterile solution type , clear glass single-dose vials gray bromobutyl rubber stopper ( made natural rubber latex ) aluminum seal snap-off cap . single-dose vials available 250 mg/50 ml ( 5 mg/ml ) strength following carton sizes : ndc 0078-0683-61 ( package 1 ) . discard unused portion . ndc 0078-0683-06 ( package 6 ) . discard unused portion . store arranon ( nelarabine ) injection 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) . usp controlled room temperature .",
    "adverseReactions": "none .",
    "indications_original": "ARRANON is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least 2 chemotherapy regimens.",
    "contraindications_original": "\u2022 Adult Dose : 1,500 mg/m 2 administered by intravenous infusion over 2 hours on Days 1, 3, and 5 repeated every 21 days. ( 2.1 ) \u2022 Pediatric Dose : 650 mg/m 2 administered by intravenous infusion over 1 hour daily for 5 consecutive days repeated every 21 days. ( 2.1 ) \u2022 Discontinue treatment for neurologic reactions greater than or equal to Grade 2. ( 2.2 ) \u2022 Dosage may be delayed for hematologic reactions. ( 2.2 ) \u2022 Take measures to prevent hyperuricemia. ( 2.4 )",
    "warningsAndPrecautions_original": "ARRANON (nelarabine) injection is supplied as a clear, colorless, sterile solution in Type I, clear glass single-dose vials with a gray bromobutyl rubber stopper (not made with natural rubber latex) and an aluminum seal with a snap-off cap.\n                  Single-dose Vials are available in 250 mg/50 mL (5 mg/mL) strength and the following carton sizes:\n                  NDC 0078-0683-61 (package of 1). Discard Unused Portion.\n                  NDC 0078-0683-06 (package of 6). Discard Unused Portion.\n                  Store ARRANON (nelarabine) Injection between 20\u00b0C and 25\u00b0C (68\u00b0F and 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F). See USP Controlled Room Temperature.",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "Arranon",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_63612"
        }
    ]
}